High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.96B
+3.88%
2.772
+4.98%
4.07B
+4.51%
3.051
+7.43%
4.20B
+6.17%
3.328
+6.65%
Estimates Revision
The market is revising Upward the revenue expectations for IQVIA Holdings Inc. (IQV) for FY2025, with the revenue forecasts being adjusted by 1.03% over the past three months. During the same period, the stock price has changed by -16.86%.
Revenue Estimates for FY2025
Revise Upward
+1.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.27%
In Past 3 Month
Stock Price
Go Down
-16.86%
In Past 3 Month
15 Analyst Rating
0Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is 181.14 USD with a low forecast of 160.00 USD and a high forecast of 211.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
4 Hold
0 Sell
Moderate Buy
0Current: 154.730
Low
160.00
Averages
181.14
High
211.00
0Current: 154.730
Low
160.00
Averages
181.14
High
211.00
Redburn Atlantic
Jamie Clark
Buy
downgrade
$255 -> $188
2025-05-23
Reason
Redburn Atlantic
Jamie Clark
Price Target
$255 -> $188
2025-05-23
downgrade
Buy
Reason
Redburn Atlantic analyst Jamie Clark lowered the firm's price target on Iqvia (IQV) to $188 from $255 and keeps a Buy rating on the shares. Iqvia lacks the potential earnings upgrades from improved demand that are possible for Charles River (CRL) through 2025, as well as any upside from a strategic review, the analyst tells investors in a research note. However, the firm believes this is already reflected in Iqvia's valuation. The company's model "provides it with a sufficient cushion to grow through the short-term factors impacting the CRO segment," contends Redburn.
Citi
Neutral
maintain
$160
2025-05-22
Reason
Citi
Price Target
$160
2025-05-22
maintain
Neutral
Reason
Citi keeps a Neutral rating on Iqvia with a $160 price target while adding a "downside 90-day short-term view" on the shares. The firm is cautious on Iqvia, citing delayed decision making by customers. The firm sees minimal upside to continued growth in the Technology and Analytics Solutions unit as comps get significantly harder in the second half of the year.
Mizuho
Ann Hynes
Outperform -> Outperform
downgrade
$210 -> $190
2025-05-15
Reason
Mizuho
Ann Hynes
Price Target
$210 -> $190
2025-05-15
downgrade
Outperform -> Outperform
Reason
Mizuho analyst Ann Hynes lowered the firm's price target on Iqvia to $190 from $210 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report.
BTIG
David Larsen
Buy -> Neutral
downgrade
2025-05-09
Reason
BTIG
David Larsen
Price Target
2025-05-09
downgrade
Buy -> Neutral
Reason
BTIG analyst David Larsen downgraded Definitive Healthcare (DH) to Neutral from Buy and removed the firm's price target. While were encouraged to hear management say on the call that churn is starting to stabilize, declines in revenue and client losses still seem to be material headwinds and it is unclear when top-line growth will rebound given that the bio-pharma market is facing pricing headwinds, the risk of tariffs, a more challenging fund-raising environment, the analyst tells investors. The firm also believes that Veeva (VEEV), Iqvia (IQV) and Doximity (DOCS) are "all very competitive," the analyst added.
HSBC
Sidharth Sahoo
Buy
to
Hold
downgrade
$260 -> $160
2025-04-25
Reason
HSBC
Sidharth Sahoo
Price Target
$260 -> $160
2025-04-25
downgrade
Buy
to
Hold
Reason
HSBC analyst Sidharth Sahoo downgraded Iqvia to Hold from Buy with a price target of $160, down from $260. The firm adjusted ratings in medical technology and life sciences are quantifying the risk/reward using stagflation, weak macro environment, and recovery scenario analyses. The market is debating whether the recent multiples correction is an opportunity to buy, or if it is the start of a potential recession, the analyst tells investors in a research note. HSBC's analysis of historical sector multiples reveals that the multiples compression might have an additional 20%-25% downside in a stagflation scenario. "We are far from the point where one can argue that these stocks are pricing in a recession," contends HSBC.
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$263 → $216
2025-04-10
Reason
Truist Securities
Jailendra Singh
Price Target
$263 → $216
2025-04-10
Maintains
Strong Buy
Reason
Truist analyst Jailendra Singh lowered the firm's price target on Iqvia to $216 from $263 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for IQVIA Holdings Inc (IQV.N) is 13.18, compared to its 5-year average forward P/E of 20.89. For a more detailed relative valuation and DCF analysis to assess IQVIA Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
20.89
Current PE
13.18
Overvalued PE
24.24
Undervalued PE
17.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Undervalued
5Y Average EV/EBITDA
15.08
Current EV/EBITDA
10.20
Overvalued EV/EBITDA
17.30
Undervalued EV/EBITDA
12.86
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
2.68
Current PS
1.64
Overvalued PS
3.10
Undervalued PS
2.26
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 581.38% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
IQV News & Events
Events Timeline
(ET)
2025-06-04
09:55:01
Early notable gainers among liquid option names on June 4th
2025-05-27 (ET)
2025-05-27
07:04:48
Rein Therapeutics says first patient dosed in Renew Phase 2 trial of LTI-03
2025-05-06 (ET)
2025-05-06
07:29:02
Iqvia backs FY25 adjusted EPS view $11.70-$12.10, consensus $11.83
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
06-17NASDAQ.COMIQV Quantitative Stock Analysis
Preview
8.5
06-17NewsfilterAI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers
Preview
7.5
06-13BenzingaNvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
Sign Up For More News
People Also Watch
FAQ
What is IQVIA Holdings Inc (IQV) stock price today?
What is IQVIA Holdings Inc (IQV)'s business?
What is the price predicton of IQV Stock?
What is IQVIA Holdings Inc (IQV)'s revenue for the last quarter?
What is IQVIA Holdings Inc (IQV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IQVIA Holdings Inc (IQV)'s fundamentals?
How many employees does IQVIA Holdings Inc (IQV). have?